US2018153951A1PendingUtilityA1

Methods for Inducing Adipocyte Browning, Improving Metabolic Flexibility, and Reducing Detrimental White Adipocyte Tissue Deposition and Dysfunction

Assignee: MEAD JOHNSON NUTRITION COPriority: Dec 5, 2016Filed: Dec 5, 2016Published: Jun 7, 2018

Est. expiryDec 5, 2036(~10.4 yrs left)· nominal 20-yr term from priority

Inventors:Yan Zhong Marieke H. Schoemaker Teartse Tim Lambers Eric A.F. Van Tol

H10W 70/461H10W 70/417H10W 72/075H10W 72/073H10W 72/884H10W 90/754H10W 72/5363H10W 90/753H10W 90/734A61K 31/202A61K 35/741A23L 33/19A23L 33/125A61K 45/06A23L 33/18A61K 31/716A23V 2002/00A23L 33/12A61K 38/018A61K 31/702

PatentIndex Score

Cited by

References

Claims

Abstract

This disclosure relates to methods of inducing adipocyte browning, supporting metabolic flexibility, and/or reducing detrimental WAT deposition or reducing WAT dysfunction in a subject by administering extensively hydrolyzed casein and/or fractions thereof (“eHC”) to the subject, and/or by administering a long chain polyunsaturated fatty acid (e.g., docosahexaenoic acid and/or arachidonic acid) to the subject.

Claims

exact text as granted — not AI-modified

What is claimed is: 
     
         1 . A method for inducing adipose browning in a subject, the method comprising administering to a subject a nutritional composition comprising
 extensively hydrolyzed casein, extensively hydrolyzed casein fractions, or combinations thereof, and/or   a long chain polyunsaturated fatty acid.   
     
     
         2 . The method of  claim 1 , wherein the nutritional composition comprises a protein source, wherein at least 1% of the protein source comprises extensively hydrolyzed casein, extensively hydrolyzed casein fractions, or combinations thereof, such that at least 1% to 80% of the protein source comprises the following individual peptides: SEQ ID NO:4, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:24, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:51, SEQ ID NO:57, SEQ ID NO:60, and SEQ ID NO:63. 
     
     
         3 . The method of  claim 2  wherein the protein source is present in amount of from about 0.2 g/100 Kcals to about 5.6 g/100 Kcals of the nutritional composition. 
     
     
         4 . The method of  claim 2 , wherein the protein source further comprises at least 10 individual peptides selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:64 and combinations thereof. 
     
     
         5 . The method of  claim 1 , wherein the nutritional composition comprises at least one long-chain polyunsaturated fatty acid. 
     
     
         6 . The method of  claim 5 , wherein the at least one long-chain polyunsaturated fatty acid is docosahexaenoic acid and arachidonic acid. 
     
     
         7 . The method of  claim 6 , wherein the docosahexaenoic acid is present in an amount from about 5 mg/100 Kcal to about 75 mg/100 Kcal. 
     
     
         8 . The method of  claim 1 , the nutritional composition further comprising a culture supernatant from a late-exponential growth phase of a probiotic batch-cultivation process. 
     
     
         9 . The method of  claim 1 , the nutritional composition further comprising a prebiotic comprising polydextrose and galacto-oligosaccharide. 
     
     
         10 . A method for increasing metabolic flexibility in a subject, the method comprising
 administering to the subject a nutritional composition comprising:   extensively hydrolyzed casein, extensively hydrolyzed casein fractions, or combinations thereof, and/or   a long chain polyunsaturated fatty acid.   
     
     
         11 . The method of  claim 10 , wherein administration of the nutritional composition to the subject when the subject is an infant increases the metabolic flexibility of the subject in adolescence and/or adulthood, and wherein metabolic flexibility is measured by:
 a. reduced plasma levels of at least one of total cholesterol, total triglycerides, free fatty acids, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the subject in response to a high fat diet, as compared to a subject who has not received the nutritional composition; or   b. decreased fasting insulin levels, improved glucose tolerance, enhanced insulin sensitivity and/or increased plasma adiponectin levels, as compared to a subject who has not received the nutritional composition.   
     
     
         12 . The method of  claim 10 , wherein the nutritional composition comprises a protein source, wherein at least 1% of the protein source comprises extensively hydrolyzed casein, extensively hydrolyzed casein fractions, or combinations thereof, such that at least 1% to 80% of the protein source comprises the following individual peptides: SEQ ID NO:4, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:24, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:51, SEQ ID NO:57, SEQ ID NO:60, and SEQ ID NO:63. 
     
     
         13 . The method of  claim 12  wherein the protein source is present in amount of from about 0.2 g/100 Kcals to about 5.6 g/100 Kcals of the nutritional composition. 
     
     
         14 . The method of  claim 11 , wherein the protein source further comprises at least 10 individual peptides selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:64 and combinations thereof. 
     
     
         15 . The method of  claim 10 , wherein the nutritional composition comprises at least one long-chain polyunsaturated fatty acid. 
     
     
         16 . The method of  claim 10 , the nutritional composition further comprising a prebiotic which comprises polydextrose and galacto-oligosaccharide. 
     
     
         17 . A method for reducing detrimental WAT deposition or reducing WAT dysfunction in a subject, the method comprising
 administering to the subject a nutritional composition comprising:   extensively hydrolyzed casein, extensively hydrolyzed casein fractions, or combinations thereof, and/or   a long chain polyunsaturated fatty acid.   
     
     
         18 . The method of  claim 17 , wherein the nutritional composition comprises a protein source, wherein at least 1% of the protein source comprises extensively hydrolyzed casein, extensively hydrolyzed casein fractions, or combinations thereof, such that at least 1% to 80% of the protein source comprises the following individual peptides: SEQ ID NO:4, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:24, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:51, SEQ ID NO:57, SEQ ID NO:60, and SEQ ID NO:63. 
     
     
         19 . The method of  claim 18  wherein the protein source is present in amount of from about 0.2 g/100 Kcals to about 5.6 g/100 Kcals of the nutritional composition. 
     
     
         20 . The method of  claim 18 , wherein the protein source further comprises at least 10 individual peptides selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:64 and combinations thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.